Mesentech
Mesentech

MES1022 Drug Conjugate

MES1022 is a drug-conjugate consisting of two parts:
1. the Targeting moiety, and
2. the Drug moiety.

The targeting moiety is a novel proprietary molecule that has high-affinity to bone. The drug moiety is a prostaglandin mimetic that acts on PGE2 receptor 4 (EP4) released from the conjugate with a half-life of 7 days. 

Mesentech

How it works

The MES1022 drug-conjugate carries the drug in an inactive state until it binds to the bone. After the targeting moiety binds to bone, the drug is released where it is received by mesenchymal stem cells, stimulating their maturation to several lineages. 

How safe is it?

We are in currently running a phase 1 human study. This study was initiated after GLP safety studies in non-human primates demonstrated it was well tolerated.